Yervoy/Nivolumab Combo Keying Bristol’s Immuno-Oncology R&D Strategy
This article was originally published in The Pink Sheet Daily
At the Morgan Stanley Healthcare Conference, recently promoted CSO Francis Cuss spoke about Bristol’s plans to test a combination of Yervoy and nivolumab in a variety of tumor types. The pharma’s near-term goals also center on label expansion for Eliquis and filing the first all-oral combination regimen for hepatitis C in Japan.
You may also be interested in...
The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.
Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.